文献速递临床试验与 GCP基础与转化研究

探究N-3脂肪酸预防新生儿烟草相关结局(INFANTS):孕妇吸烟者补充n-3多不饱和脂肪酸的双盲随机安慰剂对照平行临床试验研究方案

Investigating N-3 Fatty Acids to prevent Neonatal Tobacco-related outcomeS (INFANTS): study protocol for a double-blind, randomized, placebo-controlled parallel clinical trial of n-3 polyunsaturated fatty acids in pregnant smokers.
PubMed 文献 · Trials · 2021-12-14

INFANTS研究为多中心、随机、双盲、安慰剂对照试验,计划纳入400名孕妇吸烟者,于妊娠12至24周入组并随访至产后6周,随机接受n-3长链多不饱和脂肪酸(n-3 LCPUFA)补充或安慰剂。主要终点为分娩时孕周反映的早产,次要终点为补充12周时每日吸烟支数较基线的变化。研究假设吸烟所致n-3 LCPUFA缺乏参与烟草相关不良妊娠结局,补充可能预防这些并发症。

要点

  • 孕妇吸烟是早产、宫内生长受限和婴儿猝死综合征的重要可改变危险因素,不足半数能自行戒烟。
  • 吸烟者循环n-3 LCPUFA水平相对缺乏,近期分析显示孕期补充n-3 LCPUFA的吸烟者早产风险较非吸烟者降低。
  • 补充n-3 LCPUFA可能减少尼古丁渴求和每日吸烟量,INFANTS研究将评估其对早产和吸烟行为的影响。

核心结论

  • 研究检验吸烟诱导的n-3 LCPUFA缺乏参与烟草相关不良妊娠结局、孕期补充n-3 LCPUFA可能预防这些并发症的假设。
  • 若研究证明补充n-3 LCPUFA可有效降低烟草相关不良新生儿结局风险和/或减少孕期烟草使用,结果可能对孕期保健和新生儿结局产生即时重大影响。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照平行临床试验,计划随机400名孕妇吸烟者接受n-3 LCPUFA补充或安慰剂。
  • 参与者于妊娠12至24周入组,随访至分娩后6周,从田纳西州中部各临床中心招募。
  • 补充12周后采用自我报告和验证性烟草暴露生物标志物评估吸烟行为,用n-3 LCPUFA状态的生物标志物测量补充反应。

主要发现

  • 主要终点为分娩时孕周反映的早产。
  • 次要终点为补充12周时每日吸烟支数较基线的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tobacco use during pregnancy is the most important modifiable risk factor associated with adverse pregnancy outcomes, increasing the risk of preterm birth, intrauterine growth restriction and sudden infant death syndrome. Fewer than half of pregnant smokers can quit on their own. Identifying safe and effective therapies to prevent tobacco-related adverse pregnancy outcomes and/or increase smoking cessation in pregnant women would have a substantial public health impact. Cigarette smoking is associated with a relative deficiency in circulating n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) levels. A recent analysis found that smokers taking n-3 LCPUFAs during pregnancy had a reduction in preterm labor risk when compared to non-smokers. Studies have shown that supplemental n-3 LCPUFAs may also reduce nicotine cravings and daily cigarette use. Thus, smokers may benefit from supplemental n-3 LCPUFAs by lowering the risk of preterm labor and/or increased smoking cessation. To address important remaining knowledge gaps, we propose the Investigating N-3 Fatty Acids to prevent Neonatal Tobacco related outcomeS (INFANTS). METHODS: The INFANTS study is a multicenter, randomized, double-blind, placebo-controlled study that will randomize 400 pregnant smokers to either supplemental n-3 LCPUFAs or placebo. Participants will be enrolled between 12 and 24 weeks' gestation and followed until 6 weeks after delivery. We will recruit from clinical centers throughout Middle Tennessee. We will assess smoking behavior after 12 weeks of supplementation using self-report and validated biomarkers of tobacco exposure. We will measure response to supplementation using biological markers of n-3 LCPUFA status. Our primary endpoint will be preterm labor as reflected by gestational age at delivery. Our secondary endpoint will be change from baseline in cigarettes per day at 12 weeks. DISCUSSION: This study tests the hypothesis that smoking-induced n-3 LCPUFA deficiencies contribute to tobacco-related adverse pregnancy outcomes and that supplementation of n-3 LCPUFAs in pregnant smokers may prevent these complications. If our study demonstrates that supplemental n-3 LCPUFAs are effective at reducing the risk of tobacco-related adverse neonatal outcomes and/or reducing tobacco use during pregnancy, our results could have an immediate and major impact on pregnancy care and neonatal outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04417595. Registered on April 21, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Murff HJ, Greevy RA, Sanghani RS, et al. Investigating N-3 Fatty Acids to prevent Neonatal Tobacco-related outcomeS (INFANTS): study protocol for a double-blind, randomized, placebo-controlled parallel clinical trial of n-3 polyunsaturated fatty acids in pregnant smokers. Trials. 2021. PMID: 34906201. doi:10.1186/s13063-021-05865-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。